<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4292542</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P249</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Hilton</surname><given-names>Traci</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Sanborn</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Boulmay</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Li</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Spieler</surname><given-names>Bradley</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Happel</surname><given-names>Kyle</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Paustian</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Moudgil</surname><given-names>Tarsem</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Dubay</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Fisher</surname><given-names>Brenda</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Mederos</surname><given-names>Eileen</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Ochoa</surname><given-names>Augusto</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Urba</surname><given-names>Walter J</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Hu</surname><given-names>Hong-Ming</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Fox</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib></contrib-group><aff id="I1"><label>1</label>UbiVac, USA</aff><aff id="I2"><label>2</label>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA</aff><aff id="I3"><label>3</label>Stanley S. Scott Cancer Center, School of Medicine, LSUHSC, New Orleans, LA, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P249</fpage><lpage>P249</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Hilton et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Hilton et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P249"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Background</title><p>Tumor-derived autophagosomes, DRibbles, are novel cancer vaccines that have been shown to be effective in preclinical models of established tumors. We hypothesize that DRibbles' efficacy stems from their ability to present stabilized tumor-derived short-lived proteins (SLiPs) and defective ribosomal products (DRiPs) that are normally not processed and presented by professional antigen presenting cells (APCs). These SLiPs and DRiPs represent a potential pool of tumor antigens against which the host is not tolerant. The DPV-001 vaccine packages at least 40 putative cancer antigens, including twelve antigens from the NCI's list of prioritized antigens, multiple DAMPs and agonist activity for TLR 2, 3, 4, 7 and 9 into stable double membrane microvesicles. These microvesicles have surface f-actin and spectrin that target DRibbles to CLEC9A+ APCs, the most effective APC at cross-priming immunity.</p></sec><sec sec-type="methods"><title>Methods and Results</title><p>Patients are vaccinated at 3-week intervals with a total of 7 doses. PBMCs and serum are collected at baseline and at each vaccination. Immune monitoring panels are run on peripheral whole blood to evaluate lymphocyte populations and their activation. PBMCs from the baseline visit and week 12 are treated with DRibbles (vaccine and control) to measure vaccine specific cytokine production. Patient serum from the baseline visit and week 12 is analyzed for antibody response to &#x0003e;9000 human proteins with ProtoArrays. We have identified multiple induced and increased antibody responses, after vaccination (n = 2 patients). UbiLT3 and UbiLT6 mutations were compared to lung adenocarcinoma (LUAD) patient mutations in the TCGA database (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/public-portal/data_sets.jsp">http://www.cbioportal.org/public-portal/data_sets.jsp</ext-link>) to identify mutations shared with the DPV-001 vaccine (UbiLT3 average 78.6; UbiLT6 average 73.9 shared SNPs, excluding dbSNP (common) variants). <ext-link ext-link-type="uri" xlink:href="http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm">http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm</ext-link> was used to find the ligation strength of reference and mutated sequences on HLA types in order to predict potential T cell epitopes.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The DPV-001 vaccine provides a source of broad-spectrum relevant antigens. Preliminary analyses of patients receiving the DPV-001 vaccine show effects on T cells and increased humoral antibody responses at 12 or 13 weeks. The DPV-001 vaccine contains mutations shared with NSCLC patients in the TCGA database, including mutations with increased immunogenicity that represent potential therapeutic targets.</p></sec><sec><title>Clinical trial identifier</title><p>NCT01909752</p></sec><sec><title>Support</title><p>R44 CA121612-02A1</p></sec></body></article>